^
Association details:
| Biomarker: | KIT D816V |
|---|---|
| Cancer: | Mast Cell Leukemia |
| Drug: | Kisqali (ribociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CDK4/CDK6-INHIBITION AS A POTENT APPROACH TO AUGMENT ANTI-NEOPLASTIC EFFECTS OF MIDOSTAURIN, AVAPRITINIB AND NINTEDANIB IN KIT D816V+ NEOPLASTIC MAST CELLS
Published date:
05/12/2021
Excerpt:
The pharmacologic CDK4/CDK6-inhibitors palbociclib, ribociclib and abemaciclib were found to suppress proliferation of HMC-1 cells and ROSA cells expressing or lacking KIT D816V…
